Iopofosine I-131 (CLR 131)

Verified

Overview

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

SparkCures ID 222
Developed By Cellectar Biosciences
Generic Name Iopofosine I-131 (CLR 131)
Additional Names I-131-CLR1404, CLR131, CLR-131, CLR 131, iopofosine
Treatment Classifications
  • Phospholipid Drug Conjugate (PDC)
Tags

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
CLOVER-1
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
CLOVER-1
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

September 09, 2020

The 40% ORR (6/15 patients) represents triple class refractory patients enrolled in Part A of Cellectar’s CLOVER-1 study and additional patients enrolled in Part B from March through May 2020. As a reminder, all patients being enrolled in Part B are required to be triple class refractory. The additional six patients were heavily pre-treated with an average of 9 prior multi-drug regimens. Three patients received a total administered dose of greater than 60 mCi and three received less than 60 mCi. Consistent with the data released in February 2020, patients receiving greater than 60 mCi exhibit strong responses. Patients continue to tolerate CLR 131 well, with the most common and almost exclusive treatment emergent adverse events being cytopenias and importantly, no unexpected adverse events have been reported.

Read More

Resources

Cellectar Biosciences Expanded Access Policy

May 14, 2019

Read More
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in th...

December 16, 2019

Read More
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented...

December 09, 2019

Read More
Investigational Therapy Delivers Treatment to Patients with Multiple Myeloma in Two Doses

November 04, 2019

Read More
Cellectar Biosciences’ New Radiosensitive Therapy in Multiple Myeloma with Natalie Callander, MD ...

October 01, 2019

Read More
CLR 131 Granted Orphan Drug Status in Europe for Myeloma Treatment

September 27, 2019

Read More
CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Re...

May 15, 2019

Read More
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

May 13, 2019

Read More
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongo...

February 25, 2019

Read More
Overall Survival Lengthened for Relapsed/Refractory Myeloma Patients Using CLR 131 Cancer-Targete...

February 02, 2019

Read More
Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

January 07, 2019

Read More
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relaps...

October 02, 2018

Read More
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myelo...

August 20, 2018

Read More
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase...

November 07, 2017

Read More
Phospholipid-Ether Drug Conjugates: A Novel Vehicle Delivering Cytotoxic Small-Molecules

May 26, 2016

Read More
SparkCures Verified

SparkCures is working closely with Cellectar Biosciences to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners